The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Optimal therapy for patients who develop secondary AML after treatment with HMAs
In this video, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the optimal treatment approach for patients with myelodysplastic syndromes (MDS) who develop secondary acute myeloid leukemia (sAML) following hypomethylating agent (HMA) therapy. Dr Wang notes that while venetoclax-azacitidine (ven-aza) can result in an overall response of around 50% in this patient population, intensive induction therapy followed by allogeneic transplantation may offer better outcomes for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
